SCHEMBL2299039

SCHEMBL2299039

O=C(O)Nc1nc2ccc(C(=O)c3ccccc3C(=O)Nc3ccc(F)c(Br)c3)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.54
▸ BRAF P15056 5/20 0.54
▸ MAPT P10636 3/20 0.53
▸ CYP2C9 P11712 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ CYP2C19 P33261 2/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ CYP1A2 P05177 2/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ LMNA P02545 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ ABL1 P00519 3/20 0.48
▸ KDR P35968 2/20 0.47
▸ ABCC4 O15439 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297881 0.90 RAF1 (0.58) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL2300095 0.89 RAF1 (0.54) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL2358832 0.87 RAF1 (0.54) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL3471881 0.86 RAF1 (0.59) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL2356348 0.86 RAF1 (0.59) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL2297867 0.85 RAF1 (0.54) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL1468013 0.84 MAPT (0.50) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL3475822 0.84 RAF1 (0.59) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL2357595 0.83 RAF1 (0.56) RAF1BRAFMAPTCYP2C9ALDH1A1
SCHEMBL2357955 0.83 RAF1 (0.63) RAF1BRAFMAPTCYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback